$AJJ Medtech(584.SI)$ One chart on AJJ Medtech (SGX: 584). Morningstar’s quantitative model currently shows 4-Star, ~32% undervaluation, 75% 3Y revenue growth, and a Small Growth classification. For a micro-cap name, the key point is that AJJ is starting to show up on the market’s small-growth medtech radar. @Tiger_SG @新加坡交易所集团 @Daily_Discussion